Trials / Terminated
TerminatedNCT05632354
GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD)
An Open-label Extension Study to Evaluate the Long-term Safety of GBT021601 Administered to Participants With Sickle Cell Disease Who Have Participated in a GBT021601 Clinical Trial
- Status
- Terminated
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 47 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 6 Months
- Healthy volunteers
- Not accepted
Summary
An Open-label Extension Study of GBT021601 in Participants with Sickle Cell Disease
Detailed description
An Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of GBT021601 Administered to Participants with Sickle Cell Disease Who Have Participated in a GBT021601 Clinical Trial
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Osivelotor | Osivelotor |
Timeline
- Start date
- 2023-01-05
- Primary completion
- 2025-02-13
- Completion
- 2025-02-13
- First posted
- 2022-11-30
- Last updated
- 2026-03-19
- Results posted
- 2026-03-19
Locations
9 sites across 2 countries: United States, Nigeria
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05632354. Inclusion in this directory is not an endorsement.